Verification evidence is still being completed.
PDF / print export
Engimmune Therapeutics
Allschwil, Switzerland
- Verified lead
- Lars Nieba
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
- Review cycle
- 24 April 2026
- Full address
- Allschwil, Basel area, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- PR Newswire release confirming Lars Nieba as Chief Executive Officer of Engimmune Therapeutics.
- Editorial note
- Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
ETH Zurich spin-off, Novo Holdings investment, BaseLaunch portfolio recognition
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Allschwil, Switzerland
Engimmune Therapeutics
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering · Preclinical TCR therapeutic development
Verified 24 Apr 2026 · 2 sources
Cell TherapyDiscovery
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Contact & location
- Website
- engimmune.com
- Company page
- Lead
- Lars Nieba (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (2mo ago)
- Scale
- Preclinical TCR therapeutic development
- Capabilities
- Soluble TCR Discovery and Engineering · Protein Engineering with Machine Learning · Multi-Specific Therapeutic Design
- Founded
- 2019
- Headcount
- 11-50
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Editorial note
Engimmune Therapeutics is an ETH Zurich spin-off from the Reddy group combining protein engineering with machine learning for TCR discovery, with a named CEO, Novo Holdings investment, and BaseLaunch success-story recognition.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Verification details
Clinical profileSTATUS: VERIFIED APRIL 2026
Lars Nieba
Chief Executive Officer
Full addressAllschwil, Basel area, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
BaseLaunch success-story profile placing Engimmune in the Allschwil Basel area.
Open sourcePreclinical TCR therapeutic development
Allschwil, Switzerland. Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for future clinical development
ETH Zurich spin-off, Novo Holdings investment, BaseLaunch portfolio recognition
Capabilities
Soluble TCR Discovery and Engineering
Protein Engineering with Machine Learning
Multi-Specific Therapeutic Design
Sources
The official sources used to verify this profile.
Infrastructure
TCR discovery platform
Protein engineering workflow
Machine learning pipelines
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
Frequently asked questions
- Where is Engimmune Therapeutics located?
- Engimmune Therapeutics operates from Allschwil, Basel area, Switzerland, Allschwil, Switzerland.
- Who runs Engimmune Therapeutics?
- Engimmune Therapeutics is led by Lars Nieba, Chief Executive Officer. Verified 24 Apr 2026.
- What does Engimmune Therapeutics do?
- Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours. Core capabilities: Soluble TCR Discovery and Engineering, Protein Engineering with Machine Learning, Multi-Specific Therapeutic Design.
Editorial context
Related technical briefs
Briefs that name Allschwil as a covered market or city.